PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Intranasal Insulin Cuts Postoperative Delirium Risk; 30 IU Appears Optimal

intranasal insulinpostoperative deliriumdose-response meta-analysisrandomised controlled trialsperioperative medicinecritical careneuroprotectionoff-label usesystematic review Critical Care / ICU

Background Information

Intranasal insulin shows promise in reducing postoperative delirium.

Postoperative delirium (POD) is a common complication with serious outcomes; intranasal insulin could offer a preventive option. Intranasal insulin reduced POD risk (risk ratio 0.39) and showed maximal benefit at 30 international units (IU) with no additional effect at higher doses. The study suggests potential use of intranasal insulin to prevent POD, but further large-scale trials are needed for confirmation before clinical application. Intranasal insulin reduces POD risk most effectively at 30 IU.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Saeed O, Nounou MV, Saeed A, Rochwerg B, Abdelaziz AM, Weinhouse GL, Shim SR, Elhadi M

Citation: Saeed O, Nounou MV, Saeed A, et al. Effect of intranasal insulin on postoperative delirium: A systematic review and dose-response meta-analysis. Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine. 2026;28(4):100227. doi:10.1016/j.ccrj.2026.100227

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.